Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena administered via the CirCLIQ® on-body injector (OBI) offers a treatment experience designed with patients and HCPs in mind The first anticancer treatment to be administered through an OBI, and the first MM treatment available by both SC OBI and manual SC administration in the US Efficacy of Sarclisa now available in SC formulation with innovative OBI across app

On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who ar

Findings demonstrate significant improvements in major disruptive menopausal symptoms and a beneficial increase in E2/E1 ratio July 9, 2026 -- Elysium Health, Inc.™, the leading longevity science company, today announced new research published in Frontiers in Aging demonstrating significant improvements in disruptive menopausal symptoms in women taking Basis™, the company's flagship product clinically proven to raise NAD+ levels. The study also showed a significant increase in the ratio of estr

The University College London (UCL) sponsored study evaluates safety, tolerability and radiation dosimetry of an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical therapy, building on Blue Earth Therapeutics' radiohybrid platform. July 9, 2026 -- Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced initiation of a Phase 1 clinical trial (NCT07414940) evaluating Actinium (225Ac) rhPSMA-10.1 Injection, an investig

Ipsen announced Thursday that Dysport (abobotulinumtoxinA) hit the mark in a pair of late-stage trials, marking the first time a botulinum toxin has shown efficacy across both chronic and episodic forms of migraine. The Phase III BEOND programme enrolled 1510 adults across two studies — C-BEOND and E-BEOND — pitting Dysport against placebo, with the trials' primary efficacy endpoint being change in monthly migraine days at week 24. Top-line results showed Dysport met its primary goals in both

New patent application published covering chemically novel FAK inhibitors discovered by Amplia Application expands Amplia’s intellectual property portfolio supporting its FAK inhibitor program If granted, patent protection for the new molecules and their use would extend to 2046 New compounds broaden pipeline optionality and may support future development and partnering opportunities July 09, 2026 -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to

ART5803 is a precision therapeutic candidate designed to directly inhibit the pathogenic effects of anti-NMDA receptor autoantibodies Fast Track designation enables a more expedited regulatory review of ART5803, which has also received U.S. FDA Orphan Drug and Rare Pediatric Disease designations, as well as Orphan Drug designation from South Korea’s MFDS. Arialys Therapeutics, a clinical-stage biotechnology company pioneering precision medicines for autoimmune neuropsychiatric diseases, today

July 8, 2026 -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic medical condition that causes nodules composed primarily of excess collagen to form in the connective tissue that supports the arch of the foot. The pivotal trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in pain versus placeb

July 8, 2026 -- Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD). Tegacorat, a non-steroidal Selective Glucocorticoid Receptor Agonist and Modulator (SEGRAM), is an orally available investigational compound being developed to provide an alternative to glucocorticoid-based treatments such as prednisone, t

PDUFA target action date set for April 28, 2027 Varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors if approved Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI